Comment on

• Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.

  Duan J, Cui L, Zhao X, Bai H, Cai S, Wang G, Zhao Z, Zhao J, Chen S, Song J, Qi C, Wang Q, Huang M, Zhang Y, Huang D, Bai Y, Sun F, Lee JJ, Wang Z, Wang J. Duan J, et al. JAMA Oncol. 2020 Mar 1;6(3):375-384. doi: 10.1001/jamaoncol.2019.5367. JAMA Oncol. 2020. PMID: 31876895 Free PMC article.
• Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer.

  Ghiorghiu S, Mukhopadhyay P, Massacesi C. Ghiorghiu S, et al. JAMA Oncol. 2020 Jul 1;6(7):1115-1116. doi: 10.1001/jamaoncol.2020.0637. JAMA Oncol. 2020. PMID: 32352489 No abstract available.
• Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer.

  Wang T, Lee S, Feldman GM. Wang T, et al. JAMA Oncol. 2020 Jul 1;6(7):1115. doi: 10.1001/jamaoncol.2020.0631. JAMA Oncol. 2020. PMID: 32352495 No abstract available.
• Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer.

  Bomze D, Azoulay D, Meirson T. Bomze D, et al. JAMA Oncol. 2020 Jul 1;6(7):1114-1115. doi: 10.1001/jamaoncol.2020.0628. JAMA Oncol. 2020. PMID: 32352499 No abstract available.
• Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer.

  Deng T, Zeng G. Deng T, et al. JAMA Oncol. 2020 Jul 1;6(7):1113-1114. doi: 10.1001/jamaoncol.2020.0625. JAMA Oncol. 2020. PMID: 32352500 No abstract available.